What is the role of canakinumab in the treatment of active systemic juvenile idiopathic arthritis (JIA)?

Updated: Jul 25, 2019
  • Author: David D Sherry, MD; Chief Editor: Lawrence K Jung, MD  more...
  • Print
Answer

The interleukin-1 β inhibitor canakinumab has also been FDA-approved for systemic JIA. [39] In the beta-SPECIFIC 1 trial, 84% of patients with SJIA treated with canakinumab experienced at least a 30% improvement in symptoms compared with 10% in the placebo group after 15 days of treatment (P< 0.001). [40]

In the open-label beta-SPECIFIC 2 trial, 45% of canakinumab-treated patients who were prescribed corticosteroids were able to reduce steroid use, and one-third of patients completely discontinued corticosteroids. Additionally, the canakinumab-treated patients were nearly 3 times less likely to experience a new flare, with 74% remaining flare-free compared to 25% with placebo (P = 0.003). [40]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!